Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Executive summary

Burden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

5 evidence topics · 42 sources

Summary: epidemiology

For all stages of prostate cancer in the United States, an estimated 333,830 new cases are expected in 2026, and an estimated 3,700,086 men were living with prostate cancer in 2023. The age-adjusted incidence rate was 123.2 per 100,000 men per year (2019 to 2023 cases), and 9% of cases are diagnosed at distant stage. From 2014 through 2022 the incidence rate rose by 2.9% per year, by 4.6% per year for regional-stage disease (since 2013), and by 5.6% per year for distant-stage disease (since 2011).

A U.S. model estimated the incidence of metastatic castration-resistant prostate cancer (mCRPC) at 36,100 in 2009 and 42,970 in 2020, with 86% of incidence flowing into mCRPC states from non-metastatic castration-resistant disease. The same model estimated that 97,630 of the men living with prostate cancer in 2009 (4.4%) had metastatic disease, and projected 2020 mCRPC prevalence at 8320 (asymptomatic or minimally symptomatic, before or without progression on chemotherapy), 39,650 (symptomatic, before or without progression on chemotherapy), and 28,720 (progressed on or after first-line chemotherapy). In a review of earlier studies, 10% to 20% of men with prostate cancer developed castration-resistant disease within approximately 5 years of follow-up, and 84% or more had metastases at diagnosis of castration resistance. In Medicare fee-for-service claims, 14,780 men were newly diagnosed with mCRPC between January 2014 and June 2019. ORIC reported an annual U.S. incidence of approximately 17,000 men with mCRPC previously treated with abiraterone; this company estimate is not peer reviewed.

Androgen receptor pathway inhibitor (ARPI) use has moved into castration-sensitive disease. In a U.S. Flatiron cohort of 5361 men with mCRPC (2016 to 2023), 867 (16.2%) had received an ARPI alone before mCRPC diagnosis, a share that rose from 10.3% in 2018 to 34.8% in 2023, and 76.8% received an ARPI as first-line mCRPC treatment. In a U.S. ConcertAI cohort of 609 men (2020 to 2023), 19% had received androgen deprivation therapy (ADT) plus abiraterone and 18% ADT plus another ARPI for metastatic hormone-sensitive disease; 50% and 40% of these, respectively, received an ARPI again as first-line mCRPC treatment. In the Medicare cohort, 10% had received a novel hormonal therapy before mCRPC diagnosis.

Summary: natural history, survival, and mortality

Prostate cancer deaths are typically the result of progression to mCRPC. An estimated 36,320 U.S. deaths from prostate cancer are expected in 2026, the age-adjusted death rate was 18.9 per 100,000 men per year (2020 to 2024 deaths), and about 1 in 49 men will die of prostate cancer, the second-leading cause of cancer death in U.S. men. The decline in prostate cancer mortality slowed from 3.5% per year during the late 1990s and 2000s to 0.6% per year from 2012 through 2023. A U.S. model attributed 20.5% (2009) and 19.5% (2020) of all-cause deaths among men with prostate cancer to men with mCRPC. Five-year relative survival for distant-stage prostate cancer is 40.1%.

Median overall survival was 24.6 months in the U.S. Flatiron mCRPC cohort, with a trend toward shorter survival after prior ARPI alone or prior ARPI and taxane; 25.6 months from mCRPC diagnosis (95% CI, 25.0 to 26.2) in Medicare fee-for-service claims, where overall mortality was 54%; and 27.2 months in the ConcertAI cohort (20.8 months from first-line therapy). A review of observational studies reported median real-world overall survival of 34 months or less in most studies. In the VISION phase 3 trial, which enrolled participants previously treated with an ARPI and a taxane, median overall survival in the control group was 11.3 months. Among docetaxel-treated trial participants, median overall survival was 13.5 months with liver metastases, 19.4 months with lung metastases, 21.3 months with nonvisceral bone metastases, and 31.6 months with lymph node-only disease. These survival figures come from separate studies with different populations and are cross-study.

Bone metastases were present in 80% or more and visceral metastases in 28% or fewer of cases at mCRPC diagnosis across observational studies; in pooled docetaxel trials, 72.8% of men had bone with or without lymph node metastases, 20.8% visceral disease, and 6.4% lymph node-only disease. In the placebo group of a randomized trial of zoledronic acid, 44.2% of participants had a skeletal-related event, with a median time to first event of 321 days. Among 3,297 SEER-Medicare men with prostate cancer metastatic to bone, 40% had at least one skeletal-related event over a median follow-up of 19 months, which was associated with a higher risk of death (HR, 2.29; 95% CI, 2.09 to 2.51), highest for pathological fracture (HR, 2.77). In U.S. health systems, the cumulative incidence of skeletal-related events after diagnosis of bone metastasis from prostate cancer was 21.5% at 6 months, 30.4% at 12 months, and 41.9% at 24 months.

Summary: disease biology and resistance to androgen receptor pathway inhibitors

Castration-resistant prostate cancer continues to rely on androgen receptor (AR) signaling. In metastatic biopsies, 107 of 150 cases (71.3%) harbored AR pathway aberrations and at least 34 of 150 (22.7%) had alterations in DNA repair or recombination genes. Approximately 20% to 40% of men with mCRPC have no PSA response to enzalutamide or abiraterone, and “virtually all” initial responders acquire secondary resistance. In men with AR splice variant 7, PSA response rates were 0% with enzalutamide and with abiraterone, compared with 53% and 68% in men without it. Described resistance mechanisms fall into restored AR signaling, AR bypass signaling, and complete AR independence, including relapse with neuroendocrine features and low or absent AR expression. EZH2, the enzymatic component of polycomb repressive complex 2 (PRC2), was expressed at 2-fold higher levels in castration-resistant neuroendocrine than adenocarcinoma tumors, acts as a co-activator of the AR in castration-resistant cells, and in preclinical models EZH2 inhibitors restored AR expression and sensitivity to antiandrogen therapy.

Summary: humanistic burden

In a survey of 221 men with mCRPC and 159 caregivers in seven countries, mCRPC affected mood, emotional and mental health (50% to 77%), sleep (48% to 68%), career goals (48% to 80%), and social activities (46% to 65%); patients reported taking 7 to 12 pills per day, 52% to 73% devoted 9 hours or more per week to mCRPC care, and one in three reported persistent fatigue. Caregivers provided an average of 11 hours of care per week; 53% reported an effect on their ability to work, and among the 79% who worked outside the home before diagnosis, 40% reduced their hours and 13% stopped working. In a real-world cohort of 151 men (873 questionnaires), the mean EQ visual analog score at inclusion was 73.2 of 100, fatigue, pain, and insomnia were the most impaired domains, and these deteriorated in more than 50% of men.

Health state utility values elicited with the EQ-5D-5L from 163 men with metastatic castration-resistant disease ranged from 0.830 (asymptomatic or mildly symptomatic before chemotherapy) to 0.625 (symptomatic before chemotherapy). A meta-analysis estimated pooled mean baseline EQ-5D index values of 0.79 (95% CI, 0.70 to 0.84) in first-line treatment (7 studies) and 0.69 (95% CI, 0.67 to 0.71) in second-line or later treatment (4 studies), and EQ VAS scores of 74.63 and 65.82, respectively.

In the ARPI change group of the PSMAfore trial, which enrolled participants after progression on one ARPI, median time to worsening was 4.27 months for FACT-P total score, 3.88 months for EQ-5D-5L utility, and 3.65 months for BPI-SF pain intensity, and median time to first symptomatic skeletal event was 17.97 months. In the CARD trial, after docetaxel and one ARPI, a pain response occurred in 21 of 109 participants (19%) receiving abiraterone or enzalutamide, with a median time to pain progression of 8.5 months.

Among 281 patients in a financial toxicity study, 79 reported high financial toxicity, and those patients more often used savings to pay for treatment (62% vs 17%). Among 4,153 Medicare Part D patients filling abiraterone or enzalutamide, the median monthly out-of-pocket payment was $706 (range, $0 to $3,505) and mean adherence was 75%.

Summary: economic burden and healthcare resource utilization

Among 296 U.S. patients progressing from metastatic castration-sensitive to castration-resistant disease, mean all-cause healthcare costs per patient per month (PPPM) increased from $4,424 to $9,717 and prostate cancer-related costs from $2,859 to $8,012. In 459 commercially, Medicare Advantage-, and Medicaid-insured patients, mean total costs during first-line mCRPC therapy (average duration 8.5 months) were $13,746 all-cause and $12,061 prostate cancer-related PPPM. In Medicare fee-for-service claims, 11,528 of 14,780 men (78%) received life-prolonging therapy after mCRPC diagnosis, 6275 initiated second-line, and 2945 third-line therapy; mean all-cause medical and pharmacy costs per patient per year (2019 USD) were $27,468 in the year before diagnosis, $148,325 in first line, $160,118 in second line, and $165,186 in third line, and outpatient days per patient per year rose from 10.4 before diagnosis to 22.0 in third line. In 4758 older Medicare beneficiaries receiving first-line treatment, mean all-cause costs were $111,060 per patient per year.

Among 923 Medicare patients treated after one ARPI, 714 received a second ARPI and 209 a taxane; median overall survival was approximately 1 year in both cohorts, and serious adverse events were more frequent with a taxane (66.0% vs 42.2%). Across two U.S. data sources, 22% and 13% of taxane-treated patients received more than 8 cycles. Over 6 months of first-line treatment in employer-sponsored insurance (4,298 patients), mean gross drug payments ranged from $12,804 for docetaxel to $115,525 for sipuleucel-T. The attributable Medicare cost of at least one skeletal-related event was $21,191 (2013 USD), and hospitalizations were nearly four times as frequent among men with such an event.

Genomic testing adds cost and is applied unevenly: 674 of 5213 U.S. patients with mCRPC (13%) had a documented genetic test before PARP inhibitor approval, the biomarker testing rate in metastatic prostate cancer in a U.S. community oncology network was 34%, and tissue sequencing results were available for 72 of 150 enrolled patients in one study. A U.S. model included a next-generation sequencing cost of $5,800, and a U.S. model valued a PSMA PET scan at $6,036.17 to $6,336.17 (2021 USD), depending on the tracer.